FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589722562> ?p ?o ?g. }

• W2589722562 endingPage "1345" @default.
• W2589722562 startingPage "1339" @default.
• W2589722562 abstract "RECORD-3 compared everolimus and sunitinib as first-line therapy, and the sequence of everolimus followed by sunitinib at progression compared with the opposite (standard) sequence in patients with metastatic renal cell carcinoma (mRCC). This final overall survival (OS) analysis evaluated mature data for secondary end points.Patients received either first-line everolimus followed by second-line sunitinib at progression (n = 238) or first-line sunitinib followed by second-line everolimus (n = 233). Secondary end points were combined first- and second-line progression-free survival (PFS), OS, and safety. The impacts of neutrophil lymphocyte ratio (NLR) and baseline levels of soluble biomarkers on OS were explored.At final analysis, median duration of exposure was 5.6 months for everolimus and 8.3 months for sunitinib. Median combined PFS was 21.7 months [95% confidence interval (CI) 15.1-26.7] with everolimus-sunitinib and 22.2 months (95% CI 16.0-29.8) with sunitinib-everolimus [hazard ratio (HR)EVE-SUN/SUN-EVE, 1.2; 95% CI 0.9-1.6]. Median OS was 22.4 months (95% CI 18.6-33.3) for everolimus-sunitinib and 29.5 months (95% CI 22.8-33.1) for sunitinib-everolimus (HREVE-SUN/SUN-EVE, 1.1; 95% CI 0.9-1.4). The rates of grade 3 and 4 adverse events suspected to be related to second-line therapy were 47% with everolimus and 57% with sunitinib. Higher NLR and 12 soluble biomarker levels were identified as prognostic markers for poor OS with the association being largely independent of treatment sequences.Results of this final OS analysis support the sequence of sunitinib followed by everolimus at progression in patients with mRCC. The safety profiles of everolimus and sunitinib were consistent with those previously reported, and there were no unexpected safety signals.ClinicalTrials.gov identifier, NCT00903175." @default.
• W2589722562 created "2017-03-03" @default.
• W2589722562 creator A5005319110 @default.
• W2589722562 creator A5019077440 @default.
• W2589722562 creator A5021901636 @default.
• W2589722562 creator A5024676627 @default.
• W2589722562 creator A5027877389 @default.
• W2589722562 creator A5040180882 @default.
• W2589722562 creator A5045950154 @default.
• W2589722562 creator A5047430236 @default.
• W2589722562 creator A5058180553 @default.
• W2589722562 creator A5059063118 @default.
• W2589722562 creator A5061662378 @default.
• W2589722562 creator A5061813195 @default.
• W2589722562 creator A5068644454 @default.
• W2589722562 creator A5071569707 @default.
• W2589722562 creator A5080874435 @default.
• W2589722562 creator A5082227510 @default.
• W2589722562 creator A5082402584 @default.
• W2589722562 creator A5083103351 @default.
• W2589722562 creator A5085346419 @default.
• W2589722562 creator A5088312939 @default.
• W2589722562 date "2017-06-01" @default.
• W2589722562 modified "2023-10-17" @default.
• W2589722562 title "Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC" @default.
• W2589722562 cites W1982906652 @default.
• W2589722562 cites W2037716205 @default.
• W2589722562 cites W2070973368 @default.
• W2589722562 cites W2099088585 @default.
• W2589722562 cites W2116949558 @default.
• W2589722562 cites W2134131507 @default.
• W2589722562 cites W2138129102 @default.
• W2589722562 cites W2141444851 @default.
• W2589722562 cites W2157262448 @default.
• W2589722562 cites W2160724351 @default.
• W2589722562 cites W2222086386 @default.
• W2589722562 cites W2237254160 @default.
• W2589722562 cites W2281395530 @default.
• W2589722562 cites W2284575850 @default.
• W2589722562 cites W2298717328 @default.
• W2589722562 doi "https://doi.org/10.1093/annonc/mdx075" @default.
• W2589722562 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6290878" @default.
• W2589722562 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29390043" @default.
• W2589722562 hasPublicationYear "2017" @default.
• W2589722562 type Work @default.
• W2589722562 sameAs 2589722562 @default.
• W2589722562 citedByCount "80" @default.
• W2589722562 countsByYear W25897225622015 @default.
• W2589722562 countsByYear W25897225622016 @default.
• W2589722562 countsByYear W25897225622017 @default.
• W2589722562 countsByYear W25897225622018 @default.
• W2589722562 countsByYear W25897225622019 @default.
• W2589722562 countsByYear W25897225622020 @default.
• W2589722562 countsByYear W25897225622021 @default.
• W2589722562 countsByYear W25897225622022 @default.
• W2589722562 countsByYear W25897225622023 @default.
• W2589722562 crossrefType "journal-article" @default.
• W2589722562 hasAuthorship W2589722562A5005319110 @default.
• W2589722562 hasAuthorship W2589722562A5019077440 @default.
• W2589722562 hasAuthorship W2589722562A5021901636 @default.
• W2589722562 hasAuthorship W2589722562A5024676627 @default.
• W2589722562 hasAuthorship W2589722562A5027877389 @default.
• W2589722562 hasAuthorship W2589722562A5040180882 @default.
• W2589722562 hasAuthorship W2589722562A5045950154 @default.
• W2589722562 hasAuthorship W2589722562A5047430236 @default.
• W2589722562 hasAuthorship W2589722562A5058180553 @default.
• W2589722562 hasAuthorship W2589722562A5059063118 @default.
• W2589722562 hasAuthorship W2589722562A5061662378 @default.
• W2589722562 hasAuthorship W2589722562A5061813195 @default.
• W2589722562 hasAuthorship W2589722562A5068644454 @default.
• W2589722562 hasAuthorship W2589722562A5071569707 @default.
• W2589722562 hasAuthorship W2589722562A5080874435 @default.
• W2589722562 hasAuthorship W2589722562A5082227510 @default.
• W2589722562 hasAuthorship W2589722562A5082402584 @default.
• W2589722562 hasAuthorship W2589722562A5083103351 @default.
• W2589722562 hasAuthorship W2589722562A5085346419 @default.
• W2589722562 hasAuthorship W2589722562A5088312939 @default.
• W2589722562 hasBestOaLocation W25897225621 @default.
• W2589722562 hasConcept C126322002 @default.
• W2589722562 hasConcept C126894567 @default.
• W2589722562 hasConcept C143998085 @default.
• W2589722562 hasConcept C207103383 @default.
• W2589722562 hasConcept C2777472916 @default.
• W2589722562 hasConcept C2779490328 @default.
• W2589722562 hasConcept C2779699572 @default.
• W2589722562 hasConcept C44249647 @default.
• W2589722562 hasConcept C71924100 @default.
• W2589722562 hasConceptScore W2589722562C126322002 @default.
• W2589722562 hasConceptScore W2589722562C126894567 @default.
• W2589722562 hasConceptScore W2589722562C143998085 @default.
• W2589722562 hasConceptScore W2589722562C207103383 @default.
• W2589722562 hasConceptScore W2589722562C2777472916 @default.
• W2589722562 hasConceptScore W2589722562C2779490328 @default.
• W2589722562 hasConceptScore W2589722562C2779699572 @default.
• W2589722562 hasConceptScore W2589722562C44249647 @default.
• W2589722562 hasConceptScore W2589722562C71924100 @default.
• W2589722562 hasIssue "6" @default.
• W2589722562 hasLocation W25897225621 @default.

• next